Application of digitoflavone-7-O-beta-D-glucuronide in fundus disease treatment

A technology of glucuronide and luteolin, which can be applied in sensory diseases, cardiovascular system diseases, medical preparations containing active ingredients, etc., and can solve the problems of lack of mature methods for animal fundus diseases

Inactive Publication Date: 2012-06-27
沈阳双鼎制药有限公司
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, in terms of experimental research, there is still a lack of mature methods for causing animal fundus diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of digitoflavone-7-O-beta-D-glucuronide in fundus disease treatment
  • Application of digitoflavone-7-O-beta-D-glucuronide in fundus disease treatment
  • Application of digitoflavone-7-O-beta-D-glucuronide in fundus disease treatment

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0036] Therapeutic effect of luteolin-7-O-β-D-glucuronide on fundus diseases

[0037] (1) Determination of visual evoked potential (VER) in guinea pigs under normal conditions

[0038] 40 guinea pigs with a body weight of 200-400 g were measured according to the above method. Except for 8 animals that did not show obvious waveforms, the other 32 animals showed obvious P waves (positive phase waves) and N waves (negative phase waves).

[0039] The amplitude of P wave and N wave varies greatly among different animals, and the fluctuation is between 4-34μv. The difference between the latency of P wave and N wave among different animals is relatively small. However, the amplitude and latency of the P wave and N wave in the VER of the same animal measured at different times are similar and relatively stable. Table 1 shows the results of normal VER measurement in 64 eyes of 32 guinea pigs. It can be seen from the table that the amplitudes of the P wave and N wave of VER in both ey...

experiment example 2

[0061] Effects of Luteolin-7-O-β-D-Glucuronide on Fundus of Rabbits

[0062] There are 9 domestic rabbits weighing 1.85-2.8kg, both male and female. Take the fundus photos of both eyes before the experiment, then inject the test drug 4mg / kg intravenously, take the photos of the fundus of the two eyes under the same conditions 15 minutes after the injection, and then take the drug once a day, and take the photos of the fundus of both eyes on the seventh day, and wash the negative Take a picture enlarged 2.7 times in diameter, and measure the diameter of the fundus artery at 8mm outward from the mastoid. Changes in vessel diameter before and after administration were compared. The results are shown in Table 8.

[0063] Table 8 The expansion effect of luteolin-7-O-β-D-glucuronide on the fundus artery of rabbits

[0064]

[0065]

[0066] The results showed that the diameter of the fundus artery increased 15 minutes and seven days after administration compared with before...

experiment example 3

[0068] Therapeutic Effects of Luteolin-7-O-β-D-Glucuronide on Conjunctival Microcirculation Disturbance in Rabbits

[0069] 12 rabbits, weighing 1.5-3.0kg, both male and female. The abdominal position of the rabbit was fixed, the head was fixed, and 4-5 visual fields were observed in the middle of the eyeball of the right eye about 2 mm from the lower edge of the bulbar conjunctiva according to the above method, and 2-3 microvessels of similar thickness were observed in each visual field. Record the blood flow velocity, take the average value as the normal value before the experiment, and then intravenously infuse 10% polymer dextran saline solution 15ml / kg / day for 1-2 days, so that the microvascular blood flow velocity will be significantly slowed down, and more serious symptoms will appear. The phenomenon of blood cell aggregation, which causes microcirculation disturbance, records the blood flow velocity and blood cell aggregation. Divide the rabbits into 2 groups, 6 in ea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of digitoflavone-7-O-beta-D-glucuronide in fundus disease treatment, which is characterized in that digitoflavone-7-O-beta-D-glucuronide can be used as a main active component for preparing a medicine treating the pathological change of the fundus. One kind of or a plurality of kinds of natural or synthetic active components with a synergic or auxiliary action with the digitoflavone-7-O-beta-D-glucuronide can be added for preparing a medicine treating fundus diseases. The digitoflavone-7-O-beta-D-glucuronide is used for treating the diabetic pathological change of the retina, the senile pathological change of yellow spots, retinal vein obstruction, and the like, and has an obvious curative effect.

Description

technical field [0001] The present invention relates to a new medical application of luteolin-7-O-β-D-glucuronide, in particular to the use of luteolin-7-O-β-D-glucuronide in the preparation of medicines for treating fundus diseases The application belongs to the technical field of traditional Chinese medicine. Background technique [0002] Fundus diseases include retinal, choroidal, optic nerve and vitreous inflammation, tumors, various vascular lesions, various degenerative diseases and ocular lesions caused by multi-system diseases. Therefore, fundus diseases have always been valued by scholars from various countries, and a lot of research work has been done in different fields. At present, the common fundus diseases that seriously affect visual function include diabetic retinopathy, age-related macular degeneration, retinal vein occlusion, etc. The clinical research of these diseases has made great progress. [0003] 1. Age-related macular degeneration {aging macular d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P27/02A61P9/10
Inventor 马占芝生可心王学东王淞林于玲玲胡爽
Owner 沈阳双鼎制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap